Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

May 31, 2011

Study Completion Date

September 30, 2012

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Pazopanib

800 mg of pazopanib orally each day continuously

Trial Locations (17)

23235

Virginia Cancer Institute, Richmond

29210

South Carolina Oncology Associates, PA, Columbia

30501

Northeast Georgia Medical Center, Gainesville

30901

Medical Oncology Associates of Augusta, Augusta

32804

Florida Hospital Cancer Institute, Orlando

33705

Gulfcoast Oncology Associates, St. Petersburg

33805

Watson Clinic Center for Cancer Care and Research, Lakeland

33901

Florida Cancer Specialists, Fort Myers

37023

Tennessee Oncology, PLLC, Nashville

37404

Chattanooga Oncology Hematology Associates, Chattanooga

40207

Baptist Hospital East, Louisville

45242

Oncology Hematology Care, Cincinnati

49503

Grand Rapids Clinical Oncology Program, Grand Rapids

63017

St. Louis Cancer Care, Chesterfield

68198

University of Nebraska Medical Center, Omaha

94115

San Francisco Oncology Associates, San Francisco

04240

Central Maine Medical Center, Lewiston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER